Serum CXCL10 levels and neuromuscular manifestations in patients with autoimmune thyroid diseases

Autoimmunity

Volumn 44, Issue 6, 2011, Pages 496-503

  Cakir, Mehtap ^a   Levendoglu, Funda ^a   Kiyici, Aysel ^a   Coskun, Yasemin ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

Autoimmunity; Chemokine; Graves' disease; Hashimoto's thyroiditis; Neuromuscular

Indexed keywords

AUTOANTIBODY; DOUBLE STRANDED DNA ANTIBODY; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

ADULT; ARTICLE; AUTOIMMUNE THYROIDITIS; CARPAL TUNNEL SYNDROME; CONTROLLED STUDY; EUTHYROIDISM; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROMUSCULAR DISEASE; NEUROMUSCULAR FUNCTION; PROTEIN BLOOD LEVEL; SENSORIMOTOR FUNCTION;

ADULT; AGED; AUTOIMMUNE DISEASES; CARPAL TUNNEL SYNDROME; CHEMOKINE CXCL10; EUTHYROID SICK SYNDROMES; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR DISEASES;

EID: 80051537321     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2011.561818     Document Type: Article

References (36)

1. Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr Rev 2007;28:492-520. (Pubitemid 47236335)
2. Rotondi M, Romagnani P, Brozzetti A, Santeusanio F, Serio M, Falorni A. Serum concentrations of the interferon-inducible chemokine IP-10/CXCL10 are augmented in both newly-diagnosed type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2003;46: 1020-1021. (Pubitemid 36961328)
3. Liu C, Papewalis C, Domberg J, Scherbaum WA, Schott M. Chemokines and autoimmune thyroid diseases. Horm Metab Res 2008;40:361-368. (Pubitemid 351967125)
4. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M, Bellastella A, Serio M. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased serum levels of IP-10/CXCL10 in the serum of subjects with recent onset Graves' disease. Am J Pathol 2002;161:195-206. (Pubitemid 34760785)
5. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E, Serio M. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 2004;89:5496-5499. (Pubitemid 39518431)
6. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferrannini E, Serio M. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper-or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 2006;154:651-658. (Pubitemid 43810850)
7. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 2006;93:1226-1231. (Pubitemid 44547021)
8. Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G, Ferrannini E. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab 2007;92: 1485-1490. (Pubitemid 46556429)
9. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS, Ferrannini E. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involve¬ment in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2009;94:1803-1809.
10. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, Ferrannini E. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: Modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2006;91:614-620. (Pubitemid 43236933)
11. Kuan WP, Tam LS, Wong CK, Ko FW, Li T, Zhu T, Li EK. CXCL 9 and CXCL 10 as sensitive markers of disease activity in patients with rheumatoid arthritis. J Rheumatol 2010;37: 257-264.
12. Flytlie HA, Hvid M, Lindgreen E, Kofod-Olsen E, Petersen EL, Jørgensen A, Deleuran M, Vestergaard C, Deleuran B. Expression of MDC/CCL22 and its receptor CCR4 in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Cytokine 2010;49:24-29.
13. Yoon KC, Park CS, You IC, Choi HJ, Lee KH, Im SK, Park HY, Pflugfelder SC. Expression of CXCL9,-10,-11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Invest Ophthalmol Vis Sci 2010;51:643-650.
14. Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev 2009;8:379-383.
15. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, Panoskaltsis-Mortari A, Gregersen PK, Behrens TW, Baechler EC. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study. Arthritis Rheum 2009;60:3098-3107.
16. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, Manfredi A, Frascerra S, Franzoni F, Galetta F, Ferrannini E. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis\a longitudinal study. Rheumatology (Oxford) 2008;47:45-49. (Pubitemid 350286260)
17. Punzi L, Betterle C. Chronic autoimmune thyroiditis and rheumatic manifestations. Joint Bone Spine 2004;71: 275-283. (Pubitemid 39037314)
18. Soy M, Guldiken S, Arikan E, Altun BU, Tugrul A. Frequency of rheumatic diseases in patients with autoimmune thyroid disease. Rheumatol Int 2007;27:575-577. (Pubitemid 46411897)
19. Weetman TA. Chronic autoimmune thyroiditis. In: Braverman LE, Utiger RD, editors. Werner & Ingbar's The thyroid: A fundamental & clinical text. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. p 701-713.
20. Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, Manji N, Allahabadia A, Armitage M, Chatterjee KV, Lazarus JH, Pearce SH, Vaidya B, Gough SC, Franklyn JA. Prevalence and relative risk of other autoimmune diseases in subjects with auto¬immune thyroid disease. Am J Med 2010;123:183e1-183e9.
21. Lazúrová I, Benhatchi K, Rovenský J, Kozáková D, Wagnerová H, Tajtáková M, Shoenfeld Y, Macejova Z. Autoimmune thyroid disease and autoimmune rheumatic disorders: A two-sided analysis. Ann N YAcad Sci 2009;1173: 211-216.
22. Antonelli A, Fallahi P, Mosca M, Ferrari SM, Ruffilli I, Corti A, Panicucci E, Neri R, Bombardieri S. Prevalence of thyroid dysfunctions in systemic lupus erythematosus. Metabolism 2010;59:896-900.
23. Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, Riente L, Ferrannini E. High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. Autoimmunity 2008;41: 537-542.
24. Antonelli A, Ferri C, Fallahi P, Colaci M, Giuggioli D, Ferrari SM, Frascerra S, Franzoni F, Galetta F, Ferrannini E. Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. J Rheumatol 2008;35:1809-1811.
25. Cakir M, Samanci N, Balci N, Balci MK. Musculoskeletal manifestations in patients with thyroid disease. Clin Endocri-nol 2003;59:162-167. (Pubitemid 36918651)
26. Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann NY Acad Sci 2009;1173:310-317.
27. Cakir M. Graves' disease. In: Cakir M, editor. Differential diagnosis of hyperthyroidism, endocrinology research and clinical developments series. 1st ed. New York: Nova Science Publishers; 2010. p 1-14.
28. Gardner DF. The neuromuscular system and brain in hypothyroidism. In: Braverman LE, Utiger RD, editors. Werner & Ingbar's the thyroid: A fundamental & clinical text. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. p 836-840.
29. Rodolico C, Toscano A, Benvenga S, Mazzeo A, Bartolone S, Bartolone L, Girlanda P, Monici MC, Migliorato A, Trimarchi F, Vita G. Myopathy as the persistently isolated symptomatology of primary autoimmune hypothyroidism. Thyroid 1998;8:1033.
30. Gardner DF. The neuromuscular system and brain in thyrotoxicosis. In: Braverman LE, Utiger RD, editors. Werner & Ingbar's the thyroid: A fundamental & clinical text. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. p 637-643.
31. Manganelli P, Pavesi G, Salaffi F. Bilateral carpal tunnel syndrome in Graves' disease. Z Rheumatol 1987;46:34-35. (Pubitemid 17033719)
32. Beard L, Kumar A, Estep HL. Bilateral carpal tunnel syndrome caused by Graves' disease. Arch Intern Med 1985; 145:345-346. (Pubitemid 15166011)
33. Uchiyama S, Itsubo T, Nakamura K, Kato H, Yasutomi T, Momose T. Current concepts of carpal tunnel syndrome: Pathophysiology, treatment, and evaluation. J Orthop Sci 2010;15:1-13.
34. Atroshi I, Gummesson C, Johnsson R, Ornstein E, Ranstam J, Rosén I. Prevalence of carpal tunnel syndrome in a general population. JAMA 1999;282:153-158. (Pubitemid 29323805)
35. Nakamichi K, Tachibana S. Histology of the transverse carpal ligament and flexor tenosynovium in idiopathic carpal tunnel syndrome. J Hand Surg [Am] 1998;23:1015-1024. (Pubitemid 29102307)
36. Fuchs PC, Nathan PA, Myers LD. Synovial histology in carpal tunnel syndrome. J Hand Surg [Am] 1991;16:753-758.